NDAORALFOR SUSPENSION, DELAYED RELEASE
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
NOXAFIL POWDERMIX KIT (posaconazole) by Merck & Co. is 12. Approved for fungal infection, invasive aspergillosis, mycoses. First approved in 2021.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOXAFIL POWDERMIX KIT (posaconazole) is an azole antifungal agent indicated for prophylaxis of invasive Aspergillus and Candida infections in severely immunocompromised patients, and treatment of invasive aspergillosis. It works by inhibiting fungal cell membrane ergosterol synthesis, disrupting cell integrity and fungal growth.
Peak2.7 years to LOE
Peak lifecycle product with moderate competitive pressure (30% score) suggests stable team size and commercial focus on market share defense and clinical adoption.
Mechanism of Action
12.1 Mechanism of Action Posaconazole is an azole antifungal agent [see ] . 12.2 Pharmacodynamics Exposure Response Relationship: Prophylaxis of invasive Aspergillus and Candida Infections in Adults Who Are at High Risk of Developing These Infections Due to Being Severely Immunocompromised In…
Worked on NOXAFIL POWDERMIX KIT at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.